Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Podrobná bibliografie
Hlavní autor:	Zonderland, G
Další autoři:	Tarsounas, M
Médium:	Diplomová práce
Vydáno:	2017

Podobné jednotky

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
Autor: Tacconi, E, a další
Vydáno: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
Autor: Eliana MC Tacconi, a další
Vydáno: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
Autor: Zimmer, J, a další
Vydáno: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
Autor: Ashwin Ragupathi, a další
Vydáno: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
Autor: Tacconi, E
Vydáno: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
Autor: Ilirjana Bajrami, a další
Vydáno: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
Autor: Staples Oliver D, a další
Vydáno: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
Autor: Rebecca A. Dagg, a další
Vydáno: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
Autor: Melinda E. Snitow, a další
Vydáno: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
Autor: Giuseppa Augello, a další
Vydáno: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
Autor: Xuexia Xie, a další
Vydáno: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
Autor: Patricia A. Vignaux, a další
Vydáno: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
Autor: Hagit eEldar-Finkelman, a další
Vydáno: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
Autor: Sorin Hostiuc, a další
Vydáno: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Autor: Shicheng Yang, a další
Vydáno: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
Autor: Tingting Du, a další
Vydáno: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Autor: Karolina N. Dziadkowiec, a další
Vydáno: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Autor: Tacconi, E, a další
Vydáno: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
Autor: Qianye Yang, a další
Vydáno: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Autor: Zatreanu, D, a další
Vydáno: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
Autor: Young Ou, a další
Vydáno: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
Autor: Eliana MC Tacconi, a další
Vydáno: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
Autor: Julieta Martino, a další
Vydáno: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
Autor: Ata ur Rahman Mohammed Abdul, a další
Vydáno: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Autor: Diana Zatreanu, a další
Vydáno: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
Autor: Yosuke Akiba, a další
Vydáno: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
Autor: William B Barrell, a další
Vydáno: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
Autor: Julieta Martino, a další
Vydáno: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Autor: Przemysław Duda, a další
Vydáno: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Autor: Salar Farokhi Boroujeni, a další
Vydáno: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
Autor: Sin-Aye Park, a další
Vydáno: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
Autor: Robert A. Smith, a další
Vydáno: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
Autor: Robert A Smith, a další
Vydáno: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
Autor: Martinez, Ana, 1961-, a další
Vydáno: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Autor: Xia Ding, a další
Vydáno: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
Autor: Geoffrey I Shapiro, a další
Vydáno: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Autor: Melissa S Cline, a další
Vydáno: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Autor: Suggala Ramya Shri, a další
Vydáno: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
Autor: Rosa Buonfiglio, a další
Vydáno: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
Autor: David Ebuka Arthur, a další
Vydáno: (2020-11-01)